Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
Z Megyesfalvi, CM Gay, H Popper… - CA: a cancer journal …, 2023 - Wiley Online Library
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
Small-cell lung cancer
Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
[HTML][HTML] SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization
MK Baine, MS Hsieh, WV Lai, JV Egger… - Journal of Thoracic …, 2020 - Elsevier
Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
therapies are urgently needed. Several lines of evidence, from SCLC primary human …
[HTML][HTML] Targeting p53 for the treatment of cancer
MJ Duffy, NC Synnott, S O'Grady, J Crown - Seminars in cancer biology, 2022 - Elsevier
Dysfunction of the TP53 (p53) gene occurs in most if not all human malignancies. Two
principal mechanisms are responsible for this dysfunction; mutation and downregulation of …
principal mechanisms are responsible for this dysfunction; mutation and downregulation of …
[HTML][HTML] A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization …
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and
currently causes considerable confusion. A uniform classification framework for NENs at any …
currently causes considerable confusion. A uniform classification framework for NENs at any …
[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment …
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment …
Extracellular vesicles as tools and targets in therapy for diseases
Extracellular vesicles (EVs) are nano-sized, membranous structures secreted into the
extracellular space. They exhibit diverse sizes, contents, and surface markers and are …
extracellular space. They exhibit diverse sizes, contents, and surface markers and are …
Emerging strategies for the treatment of small cell lung cancer: a review
WJ Petty, L Paz-Ares - JAMA oncology, 2023 - jamanetwork.com
Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …
rapid growth and the early development of metastases. Patients typically respond to initial …
[HTML][HTML] MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate
Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based …